ARDT vs SGRY vs NUTX Stock Comparison

Ardent Health, Surgery Partners and Nutex Health Prices as of Nov 13, 2026 Peers: Industry group
ARDT Ardent Health, Inc.
$17.77 +48.7% 1M +91.1% 1Y
Market cap
$2.52B
P/E
17.3x
Revenue (TTM)
$6.45B
Div. yield
–
Hospitals Healthcare
2 wins
SGRY Surgery Partners, Inc.
$26.95 +81.7% 1M +76.0% 1Y
Market cap
$3.46B
P/E
–
Revenue (TTM)
$3.36B
Div. yield
–
Healthcare Services Healthcare
2 wins
NUTX Nutex Health Inc.
$173.67 -11.8% 1M +59.6% 1Y
Market cap
$1.17B
P/E
7.1x
Revenue (TTM)
$796.53M
Div. yield
0.07%
Hospitals Healthcare
6 wins

Head to Head

10 decided of 12

Nutex Health leads on 6 of the 12 questions below (Nutex Health 6, Surgery Partners 2, Ardent Health 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionARDTSGRYNUTXLeader
Larger companyMarket capitalisation $2.52B $3.46B $1.17B SGRY
Cheaper on earningsLower P/E, profitable companies only 17.3x -39.8x 7.1x NUTX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.3x 74.9x 6.2x NUTX
Faster revenue growthRevenue growth, trailing twelve months +2.0% +2.2% -18.8% SGRY
More profitableNet margin, trailing twelve months 2.3% -2.6% 20.7% NUTX
Better return on capitalReturn on invested capital 9.5% 4.5% 43.9% NUTX
Less leveragedLower net debt / EBITDA 0.6x 4.9x -0.6x NUTX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.07% –
Better 1-year returnPrice return, last 12 months +91.1% +76.0% +59.6% ARDT
Better 5-year returnAnnualised price return, 5 years — -12.1%/yr — –
Less volatileAnnualised volatility, 1 year 49.1% 61.0% 89.8% ARDT
Higher overall scoreMean of the five percentile scores vs peers 65/100 47/100 81/100 NUTX

Percentile Scorecard

ARDTSGRYNUTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisARDTSGRYNUTX
Valuation 96 #5 of 99 75 #26 of 99 92 #9 of 99
Growth 26 #66 of 89 19 #72 of 89 78 #20 of 89
Profitability 74 #25 of 92 57 #40 of 92 98 #3 of 92
Financial Health 63 #39 of 103 37 #65 of 103 87 #14 of 103
Shareholder Returns 65 #23 of 63 – 52 #31 of 63
Overall 65 47 81
  • ARDT ranked among 103 companies in Healthcare Providers
  • SGRY ranked among 103 companies in Healthcare Providers
  • NUTX ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodARDTSGRYNUTXSPY
1 month +48.7%+81.7%-11.8% -2.0%
3 months +62.7%+79.3%-7.3% -2.8%
6 months +75.9%+93.2%+37.5% +2.0%
Year to date +101.2%+74.4%+5.5% +10.6%
1 year +91.1%+76.0%+59.6% +12.2%
3 years —-10.7%+392.9% +68.1%
3 years, per year —-3.7%+70.2% +18.9%
5 years —-47.4%— +61.4%
5 years, per year —-12.1%— +10.1%
10 years —+79.1%— +248.5%
10 years, per year —+6.0%— +13.3%

Risk

MeasureARDTSGRYNUTXSPY
Volatility, 1Y 49.1%61.0%89.8% 13.6%
Downside volatility, 1Y 44.8%49.3%88.2% 13.9%
Beta vs S&P 500, 1Y 0.291.061.76 1.00
Return / volatility, 1Y 1.861.250.66 0.90
Max drawdown, 5Y -61.2%-81.4%-99.9% -25.4%
From 52-week high -2.3%0.0%-22.8% -3.2%
52-week high $18.18$26.95$225.00 $779.14
52-week low $7.83$11.49$87.01 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleARDTSGRYNUTX
P/E now vs peer median 17.1xmedian 22.4x -39.9xmedian 22.4x 7.2xmedian 22.4x
P/S now vs peer median 0.4xmedian 1.3x 1.0xmedian 1.3x 1.5xmedian 1.3x
EV/EBITDA now vs peer median 5.5xmedian 14.2x 11.3xmedian 14.2x 2.9xmedian 14.2x
P/FCF now vs peer median 8.9xmedian 19.0x 17.4xmedian 19.0x 4.8xmedian 19.0x
P/B now vs peer median 1.4xmedian 2.6x 1.2xmedian 2.6x 2.2xmedian 2.6x
PEG now vs peer median —median 0.84 1.13median 0.84 0.07median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsARDTSGRYNUTX
Revenue $6.45B $3.36B $796.53M
Gross profit $5.35B $747.60M $380.67M
Operating income $343.67M $363.70M $311.00M
Net income $194.40M $1.70M $233.03M
Free cash flow $282.30M $202.80M $248.10M
EPS (diluted) $1.03 $-0.68 $23.39
Cash & equivalents $766.24M $354.50M $249.91M
Total debt $1.10B $3.06B $42.37M
Shares (diluted) 141.70M 128.87M 7.04M
Enterprise value -$286.35M $2.47B $315.47M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricARDTSGRYNUTX
P/E 17.1x -39.9x 7.2x
P/FCF 8.9x 17.4x 4.8x
P/Operating cash flow 5.2x 12.7x 4.6x
P/S 0.4x 1.0x 1.5x
P/B 1.4x 1.2x 2.2x
P/Tangible book 1.5x 1.2x 2.3x
EV/EBITDA 5.5x 11.3x 2.9x
EV/EBIT 8.3x 17.1x 3.2x
EV/Revenue 0.4x 1.9x 1.2x
EV/FCF 10.0x 30.7x 3.9x
EV/Operating cash flow 5.9x 22.4x 3.8x
PEG (3Y EPS CAGR) – 1.13 0.07

Growth

14 metrics
MetricARDTSGRYNUTX
Revenue growth (1Y) 2.0% 2.2% -18.8%
Revenue CAGR (3Y) – 7.4% 50.9%
Gross profit growth (1Y) 1.7% -4.9% -29.5%
Gross profit CAGR (3Y) – -92.0% 158.3%
Operating income growth (1Y) -17.7% -10.5% -13.4%
Operating income CAGR (3Y) – 4.3% 208.2%
Net income growth (1Y) -16.1% 102.2% -11.6%
Net income CAGR (3Y) – -72.9% 121.3%
EPS growth (1Y) -28.9% 49.9% 46.8%
EPS CAGR (3Y) – -35.3% 96.4%
Operating cash flow growth (1Y) 31.4% -1.6% 45.4%
Operating cash flow CAGR (3Y) – 5.2% 224.9%
Free cash flow growth (1Y) 79.3% 4.5% 40.7%
Free cash flow CAGR (3Y) – 11.4% 237.1%

Profitability

14 metrics
MetricARDTSGRYNUTX
Gross margin 82.8% 22.2% 47.8%
EBITDA margin 8.0% 16.4% 41.8%
Operating margin 5.3% 10.8% 39.0%
Pretax margin 4.5% 2.7% 36.7%
Net margin 2.3% -2.6% 20.7%
FCF margin 4.4% 6.0% 31.1%
Operating cash flow margin 7.5% 8.3% 32.4%
Return on equity 13.1% 2.4% 44.5%
Return on assets 4.3% 0.9% 23.3%
Return on invested capital 9.5% 4.5% 43.9%
Return on capital employed 8.0% 5.2% 35.9%
Asset turnover 1.2x 0.4x 0.8x
Cash conversion (OCF / net income) 2.5x 163.5x 1.1x
Stock comp / revenue 0.5% 0.4% 0.5%

Financial Health

11 metrics
MetricARDTSGRYNUTX
Debt / assets 20.5% 43.3% 4.1%
Debt / equity 0.6x 1.1x 0.1x
Net debt / EBITDA 0.6x 4.9x -0.6x
Debt / FCF 3.9x 15.1x 0.2x
Liabilities / assets 66.6% 58.9% 47.6%
Equity / assets 33.4% 41.1% 52.4%
Interest coverage 6.5x – 16.2x
Current ratio 2.1x 2.2x 4.8x
Quick ratio 1.4x 1.6x 4.7x
Cash ratio 0.8x 0.7x 1.9x
Altman Z-score 2.26 1.08 3.62

Shareholder Returns

7 metrics
MetricARDTSGRYNUTX
Dividend yield – – –
Net buyback yield 0.4% – -0.2%
Shareholder yield 0.4% – -0.2%
Payout ratio (earnings) – – 36.8%
Payout ratio (FCF) – – 34.6%
Dividend growth (1Y) – – 90.9%
Dividend CAGR (3Y) – – 148.5%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusARDTSGRYNUTX
Forward P/E 17.3xFY2026 74.9xFY2026 6.2xFY2026
EPS, next fiscal year $1.03FY2026 $0.36FY2026 $28.17FY2026
EPS growth, next FY +7.3%FY2026 -23.4%FY2026 +168.8%FY2026
EPS growth, the year after +12.6% -22.2% -7.0%
Revenue, next fiscal year $6.86BFY2026 $3.31BFY2026 $824.69MFY2026
Revenue growth, next FY +8.5%FY2026 0.0%FY2026 -5.8%FY2026
Revenue growth, the year after +0.4% -7.7% +19.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersARDTSGRYNUTX
Held by institutions 76.4% 100.0% 42.8%
Institutions holding 137 191 154
Change in shares held, QoQ +1.4% -0.8% +5.8%
Institutions buying 87 113 100
Institutions selling 36 50 36
Buyers to sellers 2.42 2.26 2.78

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ARDTSGRYNUTX
ARDT 1.00 0.21 0.08
SGRY 0.21 1.00 0.14
NUTX 0.08 0.14 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ARDT, SGRY and NUTX?

Surgery Partners (SGRY) is the largest by market capitalisation: Ardent Health (ARDT) $2.52B, Surgery Partners (SGRY) $3.46B, Nutex Health (NUTX) $1.17B.

Which stock is cheaper, ARDT, SGRY and NUTX?

Nutex Health (NUTX) trades on the lowest price-to-earnings ratio (Ardent Health (ARDT) 17.3x, Surgery Partners (SGRY) -39.8x, Nutex Health (NUTX) 7.1x). On next year's consensus earnings, Nutex Health (NUTX) is cheapest (Ardent Health (ARDT) 17.3x, Surgery Partners (SGRY) 74.9x, Nutex Health (NUTX) 6.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Surgery Partners (SGRY) grew revenue fastest over the trailing twelve months: Ardent Health (ARDT) +2.0%, Surgery Partners (SGRY) +2.2%, Nutex Health (NUTX) -18.8%.

Which company is more profitable?

Nutex Health (NUTX) has the highest net margin (Ardent Health (ARDT) 2.3%, Surgery Partners (SGRY) -2.6%, Nutex Health (NUTX) 20.7%). On return on invested capital, Nutex Health (NUTX) leads (Ardent Health (ARDT) 9.5%, Surgery Partners (SGRY) 4.5%, Nutex Health (NUTX) 43.9%).

Which stock has performed better?

Over the past year Ardent Health (ARDT) returned the most: Ardent Health (ARDT) +91.1%, Surgery Partners (SGRY) +76.0%, Nutex Health (NUTX) +59.6%. Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Ardent Health (ARDT) 0.00%, Surgery Partners (SGRY) 0.00%, Nutex Health (NUTX) 0.07%. Ardent Health (ARDT) and Surgery Partners (SGRY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Ardent Health (ARDT) has been the steadiest (Ardent Health (ARDT) 49.1%, Surgery Partners (SGRY) 61.0%, Nutex Health (NUTX) 89.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ARDT, SGRY and NUTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Nutex Health (NUTX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.